Evidence map›Paper›PMID 42167247›Full record

ArticleCell reports. Medicine2026

Circulating cell-free mtDNA fragmentomics for early detection of gastric cancer and precancerous lesions.

Miao Dang, Siyuan Wang, Huanqin Zhang, Hengmin Xu, Linzhi Lu, Yue Liu, Huanmin Jiao, Wenying Yang, Fan Peng, Xianchun Gao and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Miao DangState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Physiology and Pathophysiology, Fourth Military Medical University, Xi'an, China.
Siyuan WangState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Physiology and Pathophysiology, Fourth Military Medical University, Xi'an, China.
Huanqin ZhangState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Physiology and Pathophysiology, Fourth Military Medical University, Xi'an, China.
Hengmin XuState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing, China.
Linzhi LuWuwei Heavy Ion Radiotherapy Center, Gansu Wuwei Tumor Hospital, Wuwei, China.
Yue LiuState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Physiology and Pathophysiology, Fourth Military Medical University, Xi'an, China.
Huanmin JiaoState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Physiology and Pathophysiology, Fourth Military Medical University, Xi'an, China.
Wenying YangCollege of Medical Technology, Shaanxi University of Chinese Medicine, Xianyang, China.
Fan PengState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Physiology and Pathophysiology, Fourth Military Medical University, Xi'an, China.
Xianchun GaoState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China.
Fang LinState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and Department of Clinical Diagnosis, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Ke DongState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and Department of Clinical Diagnosis, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Kaifeng PanState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing, China.
Wenqing LiState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing, China.
Renquan LuDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Yongzhan NieState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China. Electronic address: yongznie@fmmu.edu.cn.
Yang LiuState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and Department of Clinical Diagnosis, Tangdu Hospital, Fourth Military Medical University, Xi'an, China. Electronic address: liuyangfmmu@163.com.
Jinliang XingState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Physiology and Pathophysiology, Fourth Military Medical University, Xi'an, China. Electronic address: xingjl@fmmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer (GC) requires non-invasive early detection beyond insensitive serum biomarkers and invasive endoscopy. Circulating cell-free mitochondrial DNA (ccf-mtDNA) fragmentomics offers liquid biopsy potential. Using capture-based deep sequencing in 1,951 participants across multiple centers, we develop a random forest-based GC detection (GD) model. The GD model achieves high accuracy for GC (sensitivity >90%, specificity >93%). In a nested case-control study (42 GC cases, 42 matched controls), it detects preclinical GC with time-dependent sensitivity from 62.50% (>3 years pre-diagnosis) to 85.71% (<2 years) and stable specificity (88.89%-100%). For high-grade dysplasia, the model shows superior sensitivity to serum biomarkers (83.10% vs. 25.00%, p < 0.001). In other gastrointestinal cancers (n = 194), the area under the curve is 0.7477 with a specificity of 70.10%. ccf-mtDNA fragmentomics thus enables the accurate, non-invasive detection of GC and its precursors, supporting clinical diagnosis and risk management.

Indexed as

Cell-Free Nucleic AcidsDNA, MitochondrialEarly Detection of CancerPrecancerous ConditionsStomach NeoplasmsAgedBiomarkers, TumorCase-Control StudiesFemaleHumansLiquid BiopsyMaleMiddle AgedBiomarkers, TumorCell-Free Nucleic AcidsDNA, Mitochondrialcirculating cell-free mitochondrial DNAearly detectionfragmentomicsgastric cancerprecancerous lesionprospective study

Identifiers

PMID42167247
PMCPMC13293960

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.